HanAll Biopharma clarified that the new FcRn inhibitor HL161ANS (IMVT-1402), unveiled by its licensed partner Immunovant as a new development program, is a compound discovered and developed by HanAll. Both batoclimab and HL161ANS compounds were licensed to Roivant Sciences in regions including North America, South America, and Europe in 2017. HL161ANS demonstrated deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein in animal studies.